Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 3/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976371 | 0.81 | CDC7 (0.68) | KDM4EALDH1A1KMT2AHPGDAPOBEC3G | |
| SCHEMBL16039727 | 0.78 | KDM4E (0.68) | KDM4EALDH1A1KMT2AAPOBEC3GRAB9A | |
| SCHEMBL14148621 | 0.74 | ALDH1A1 (0.72) | KDM4EALDH1A1KMT2APPARGNCOA2 | |
| SCHEMBL16037743 | 0.70 | LMNA (0.74) | KDM4EALDH1A1KMT2AHPGDMEN1 | |
| SCHEMBL11463722 | 0.70 | IDO1 (0.57) | KDM4EALDH1A1KMT2AAPOBEC3GRAB9A | |
| SCHEMBL12335736 | 0.70 | KMT2A (0.67) | KDM4EALDH1A1KMT2APPARGNCOA2 | |
| SCHEMBL14148651 | 0.69 | KMT2A (0.57) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL544437 | 0.69 | KDM4E (0.52) | KDM4EALDH1A1KMT2AAPOBEC3GRAB9A | |
| SCHEMBL12076664 | 0.68 | MEN1 (0.58) | KDM4EALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL12335590 | 0.68 | KMT2A (0.64) | KDM4EALDH1A1KMT2APPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | claimed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | claimed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | claimed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850218-B2 | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC Foundation for Research Development (10 pp.) | 2016-05-12 | — | — | US | disclosed |
| WO-2014160197-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275178-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | KDM4E 4514/4885ALDH1A1 145/4885KMT2A 4254/4885 |
| US-20160130241-A1 | THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | TTR, PPARG, PPARD | KDM4E 4514/4885ALDH1A1 145/4885KMT2A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.